Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models, and mechanisms

Annual Review of Pathology: Mechanisms of Disease

Volumn 7, Issue , 2012, Pages 423-467

  Sotgia, Federica ^a,b,d   Martinez Outschoorn, Ubaldo E ^a,b,c   Howell, Anthony ^d   Pestell, Richard G ^a,b,c   Pavlides, Stephanos ^a,b,d   Lisanti, Michael P ^a,b,c,d  

^a Regenerative Medicine Center   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aerobic glycolysis; Autophagy; Biomarkers; Cancer cell metabolism; Cancer associated fibroblasts; Tumor microenvironment

Indexed keywords

CARBONATE DEHYDRATASE IX; CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; CYCLIN D1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FUMARATE HYDRATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOCITRATE DEHYDROGENASE; METFORMIN; PLATELET DERIVED GROWTH FACTOR; QUERCETIN; RAS PROTEIN; SMALL INTERFERING RNA; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CANCER SIZE; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CITRIC ACID CYCLE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; LACTIC ACIDOSIS; LUNG FIBROSIS; LYMPH NODE METASTASIS; MEMBRANE TRANSPORT; MESENCHYMAL STEM CELL; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR REPROGRAMMING; OLIGOMERIZATION; ONCOGENE C MYC; OVERALL SURVIVAL; OXIDATIVE COUPLING; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; AUTOPHAGY; CAVEOLIN 1; CELL PROLIFERATION; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PARACRINE COMMUNICATION; TUMOR MICROENVIRONMENT;

EID: 84855434874     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-011811-120856     Document Type: Review

References (300)

1. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, et al. 1999. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19:7289-304 (Pubitemid 29493393)
2. Song KS, Tang Z, Li S, Lisanti MP. 1997. Mutational analysis of the properties of caveolin-1. A novel role for the C-terminal domain in mediating homotypic caveolin-caveolin interactions. J. Biol. Chem. 272:4398-403 (Pubitemid 27078516)
3. Liu L, Pilch PF. 2008. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization. J. Biol. Chem. 283:4314-22
4. Liu L, Brown D, McKeeM, Lebrasseur NK, Yang D, et al. 2008. Deletion of cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab. 8:310-17
5. Anderson RG. 1998. The caveolae membrane system. Annu. Rev. Biochem. 67:199-225 (Pubitemid 28411129)
6. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, et al. 1999. Expression of caveolin-1 is required for the transport of caveolin-2 to the plasma membrane. Retention of caveolin-2 at the level of the Golgi complex. J. Biol. Chem. 274:25718-25
7. Drab M, Verkade P, Elger M, Kasper M, Lohn M, et al. 2001. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293:2449-52 (Pubitemid 32917325)
8. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, et al. 2001. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:38121-38
9. Galbiati F, Engelman JA, Volonte D, Zhang XL, Minetti C, et al. 2001. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities. J. Biol. Chem. 276:21425-33
10. Glenney JR Jr, Soppet D. 1992. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus-transformed fibroblasts. Proc. Natl. Acad. Sci. USA 89:10517-21
11. Fielding PE, Chau P, Liu D, Spencer TA, Fielding CJ. 2004. Mechanism of platelet-derived growth factor-dependent caveolin-1 phosphorylation: relationship to sterol binding and the role of serine-80. Biochemistry 43:2578-86 (Pubitemid 38327853)
12. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, et al. 2000. Constitutive and growth factor- regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol. 14:1750-75
13. Sanguinetti AR, Mastick CC. 2003. c-Abl is required for oxidative stress-induced phosphorylation of caveolin-1 on tyrosine 14. Cell Signal 15:289-98 (Pubitemid 36071673)
14. Volonte D, Galbiati F, Pestell RG, Lisanti MP. 2001. Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress. J. Biol. Chem. 276:8094-103
15. Schlegel A, Schwab RB, Scherer PE, Lisanti MP. 1999. A role for the caveolin scaffolding domain in mediating the membrane attachment of caveolin-1. The caveolin scaffolding domain is both necessary and sufficient for membrane binding in vitro. J. Biol. Chem. 274:22660-67
16. Woodman SE, Schlegel A, Cohen AW, Lisanti MP. 2002. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. Biochemistry 41:3790-95 (Pubitemid 34224693)
17. Sargiacomo M, Scherer PE, Tang Z, Kubler E, Song KS, et al. 1995. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc. Natl. Acad. Sci. USA 92:9407-11
18. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. 1993. Signal transducing molecules and glycosylphosphatidylinositol- linked proteins form a caveolin-rich insoluble complex in MDCK cells. J. Cell Biol. 122:789-807 (Pubitemid 23241090)
19. LisantiMP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, et al. 1994. Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell Biol. 126:111-26 (Pubitemid 24214933)
20. LisantiMP, Scherer PE, Tang Z, Sargiacomo M. 1994. Caveolae, caveolin and caveolin-rich membrane domains: a signaling hypothesis. Trends Cell Biol. 4:231-35 (Pubitemid 24190653)
21. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. 1997. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272:6525-33 (Pubitemid 27118133)
22. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. 1998. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273:5419-22 (Pubitemid 28123999)
23. Feron O, Belhassen L, Kobzik L, Smith TW, Kelly RA, Michel T. 1996. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J. Biol. Chem. 271:22810-14 (Pubitemid 26304729)
24. Li S, Couet J, Lisanti MP. 1996. Src tyrosine kinases, Gα subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the autoactivation of Src tyrosine kinases. J. Biol. Chem. 271:29182-90 (Pubitemid 26382628)
25. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, et al. 1997. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J. Biol. Chem. 272:33416-21 (Pubitemid 28023695)
26. Couet J, Sargiacomo M, Lisanti MP. 1997. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272:30429-38 (Pubitemid 27512253)
27. Razani B, Woodman SE, Lisanti MP. 2002. Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54:431-67
28. Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP. 2004. Caveolinopathies: Mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62:538-43 (Pubitemid 38252792)
29. Gazzerro E, Sotgia F, Bruno C, Lisanti MP, Minetti C. 2010. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur. J. Hum. Genet. 18:137-45
30. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, et al. 1998. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18:365-68 (Pubitemid 28158166)
31. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, et al. 2006. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 114:2104-12 (Pubitemid 44747890)
32. Minetti C, Bado M, Broda P, Sotgia F, Bruno C, et al. 2002. Impairment of caveolae formation and Tsystem disorganization in human muscular dystrophy with caveolin-3 deficiency.Am. J. Pathol. 160:265-70 (Pubitemid 34052287)
33. Michel JB, Feron O, Sacks D, Michel T. 1997. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J. Biol. Chem. 272:15583-86 (Pubitemid 27265522)
34. Garcia-Cardena G, Martasek P, Masters BS, Skidd PM, Couet J, et al. 1997. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J. Biol. Chem. 272:25437-40 (Pubitemid 27438846)
35. Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. 1996. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. USA 93:6448-53 (Pubitemid 26230326)
36. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, et al. 1996. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J. Biol. Chem. 271:6518-22 (Pubitemid 26095467)
37. Liu J, Garcia-Cardena G, Sessa WC. 1996. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 35:13277-81 (Pubitemid 26349419)
38. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. 1996. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 271:27237-40 (Pubitemid 26367273)
39. Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, et al. 2009. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J. Clin. Investig. 119:2009-18
40. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, et al. 2000. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6:1362-67 (Pubitemid 32001020)
41. Paxinou E, Weisse M, Chen Q, Souza JM, Hertkorn C, et al. 2001. Dynamic regulation of metabolism and respiration by endogenously produced nitric oxide protects against oxidative stress. Proc. Natl. Acad. Sci. USA 98:11575-80 (Pubitemid 32928770)
42. Williams TM, Lee H, Cheung MW, Cohen AW, Razani B, et al. 2004. Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia. J. Biol. Chem. 279:24745-56 (Pubitemid 38725342)
43. Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, et al. 2001. Caveolin-1 expression negatively regulates cell cycle progression by inducingG0/G1 arrest via a p53/p21WAF1/Cip1-dependent mechanism. Mol. Biol. Cell 12:2229-44 (Pubitemid 33051953)
44. Hulit J, Bash T, Fu M, Galbiati F, Albanese C, et al. 2000. The cyclin D1 gene is transcriptionally repressed by caveolin-1. J. Biol. Chem. 275:21203-9 (Pubitemid 30481815)
45. Williams TM, Cheung MW, Park DS, Razani B, Cohen AW, et al. 2003. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol. Biol. Cell 14:1027-42 (Pubitemid 36337450)
46. Liu P, Ying Y, Ko YG, Anderson RG. 1996. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J. Biol. Chem. 271:10299-303 (Pubitemid 26132521)
47. Mineo C, James GL, Smart EJ, Anderson RG. 1996. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem. 271:11930-35 (Pubitemid 26157268)
48. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. 1996. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J. Biol. Chem. 271:9690-97
49. Liu P, Ying Y, Anderson RG. 1997. Platelet-derived growth factor activates mitogen-activated protein kinase in isolated caveolae. Proc. Natl. Acad. Sci. USA 94:13666-70 (Pubitemid 28009640)
50. Engelman JA, Chu C, Lin A, Jo H, Ikezu T, et al. 1998. Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett. 428:205-11 (Pubitemid 28319685)
51. Engelman JA, Lee RJ, Karnezis A, Bearss DJ, Webster M, et al. 1998. Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J. Biol. Chem. 273:20448-55 (Pubitemid 28377612)
52. Zhang W, Razani B, Altschuler Y, Bouzahzah B, Mostov KE, et al. 2000. Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem. 275:20717-25 (Pubitemid 30457660)
53. Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, et al. 1998. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17:6633-48 (Pubitemid 28521797)
54. Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, et al. 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279:51630-46 (Pubitemid 40017914)
55. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP. 1997. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272:16374-81 (Pubitemid 27276462)
56. Cerezo A, Guadamillas MC, Goetz JG, Sanchez-Perales S, Klein E, et al. 2009. The absence of caveolin- 1 increases proliferation and anchorage-independent growth by a Rac-dependent, Erk-independent mechanism. Mol. Cell. Biol. 29:5046-59
57. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat. Rev. Cancer 6:392-401
58. Amatangelo MD, Bassi DE, Klein-Szanto AJ, Cukierman E. 2005. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 167:475-88 (Pubitemid 43026103)
59. Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. 2003. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res. Treat. 81:137-47 (Pubitemid 37211131)
60. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, et al. 2008. Collagen density promotes mammary tumor initiation and progression. BMC Med. 6:11
61. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, et al. 2009. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139:891-906
62. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, et al. 2002. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumor invasion and progression. Eur. J. Cancer 38:2362-70 (Pubitemid 35387487)
63. Ronnov-Jessen L, Petersen OW. 1993. Induction of α-smooth muscle actin by transforming growth factor β1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Investig. 68:696-707 (Pubitemid 23202798)
64. Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, et al. 2004. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64:8492-95 (Pubitemid 39552057)
65. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, et al. 2008. Carcinoma-associated fibroblast- like differentiation of human mesenchymal stem cells. Cancer Res. 68:4331-39
66. Mueller L, Goumas FA, Affeldt M, Sandtner S, Gehling UM, et al. 2007. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am. J. Pathol. 171:1608-18 (Pubitemid 350158321)
67. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, et al. 2003. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am. J. Pathol. 162:391-402 (Pubitemid 36267847)
68. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. 2007. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67:10123-28 (Pubitemid 350070783)
69. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, et al. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-48 (Pubitemid 40692295)
70. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. 2007. Mesenchymal stem cells within tumor stroma promote breast cancer metastasis. Nature 449:557-63 (Pubitemid 47525152)
71. Shekhar MP, Pauley R, Heppner G. 2003. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 5:130-35 (Pubitemid 36519405)
72. Dvorak HF. 1986. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315:1650-59 (Pubitemid 17052899)
73. Sieweke MH, Thompson NL, Sporn MB, Bissell MJ. 1990. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-sβ. Science 248:1656-60
74. Shao ZM, Nguyen M, Barsky SH. 2000. Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19:4337-45
75. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, et al. Autocrine TGF-sβand stromal cell-derived factor 1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. USA 107:20009-14
76. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. 2008. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14:518-27 (Pubitemid 351655218)
77. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. 2009. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat. Med. 15:68-74
78. Surowiak P, Murawa D, Materna V, Maciejczyk A, Pudelko M, et al. 2007. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 27:2917-24 (Pubitemid 47228021)
79. Tsujino T, Seshimo I, Yamamoto H, Ngan CY, Ezumi K, et al. 2007. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 13:2082-90 (Pubitemid 46649876)
80. Hagglof C, Hammarsten P, Josefsson A, Stattin P, Paulsson J, et al. Stromal PDGFR? expression in prostate tumors and nonmalignant prostate tissue predicts prostate cancer survival. PLoS ONE 5:e10747
81. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, et al. 2009. An absence of stromal caveolin- 1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am. J. Pathol. 174:2023-34
82. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, et al. 2009. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am. J. Pathol. 174:2035-43
83. Howell A, Landberg G, Bergh J. 2009. Breast tumor stroma is a prognostic indicator and target for therapy. Breast Cancer Res. 11(Suppl. 3):16
84. Peinado H, Moreno-Bueno G, Hardisson D, Perez-Gomez E, Santos V, et al. 2008. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res. 68:4541-50
85. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, et al. 2010. Allosteric inhibition of lysyl oxidase-like 2 impedes the development of a pathologic microenvironment. Nat. Med. 16:1009-17
86. Santos AM, Jung J, Aziz N, Kissil JL, Pure E. 2009. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J. Clin. Investig. 119:3613-25
87. Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, et al. 2010. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol. Ther. 10:125-43
88. Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, et al. 2009. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol. Ther. 8:1071-79
89. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. 2009. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 8:2420-24
90. Koleske AJ, Baltimore D, Lisanti MP. 1995. Reduction of caveolin and caveolae in oncogenically transformed cells. Proc. Natl. Acad. Sci. USA 92:1381-85
91. Timme TL, Goltsov A, Tahir S, Li L, Wang J, et al. 2000. Caveolin-1 is regulated by c-Myc and suppresses c-Myc-induced apoptosis. Oncogene 19:3256-65 (Pubitemid 30487412)
92. Park DS, Razani B, Lasorella A, Schreiber-Agus N, Pestell RG, et al. 2001. Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry 40:3354-62 (Pubitemid 32221638)
93. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP. 2000. Caveolin-1 expression is downregulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 39:13916-24
94. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. 1998. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16:1391-97 (Pubitemid 28151846)
95. Yang G, Timme TL, Naruishi K, Fujita T, Fattah el MA, et al. 2008. Mice with cav-1 gene disruption have benign stromal lesions and compromised epithelial differentiation. Exp. Mol. Pathol. 84:131-40
96. LeeH, ParkDS, Razani B, Russell RG, Pestell RG, Lisanti MP. 2002. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1-/- null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161:1357-69
97. Capozza F, Williams TM, Schubert W, McClain S, Bouzahzah B, et al. 2003. Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am. J. Pathol. 162:2029-39 (Pubitemid 36613059)
98. Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, et al. 2009. Genetic ablation of caveolin-1 drives estrogen hypersensitivity and the development of DCIS-like mammary lesions. Am. J. Pathol. 174:1172-90
99. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, et al. 2006. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am. J. Pathol. 169:1784-801 (Pubitemid 351182008)
100. Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, et al. 2003. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. Am. J. Physiol. Cell Physiol. 284:457-74
101. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, et al. 2008. Decreased expression of caveolin-1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 58:2854-65
102. Razani B, Zhang XL, BitzerM, von Gersdorff G, Bottinger EP, Lisanti MP. 2001. Caveolin-1 regulates transforming growth factor (TGF)-β/SMAD signaling through an interaction with the TGF-sβtype I receptor. J. Biol. Chem. 276:6727-38
103. Wang XM, Zhang Y, KimHP, Zhou Z, Feghali-Bostwick CA, et al. 2006. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 203:2895-906 (Pubitemid 46026167)
104. Wunderlich C, Schmeisser A, Heerwagen C, Ebner B, Schober K, et al. 2008. Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulm. Pharmacol. Ther. 21:507-15 (Pubitemid 351625932)
105. Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. 2010. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am. J. Pathol. 176:2626-37
106. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, et al. 2006. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am. J. Respir. Crit. Care Med. 173:112-21 (Pubitemid 43069796)
107. Nho RS, Xia H, Diebold D, Kahm J, Kleidon J, et al. 2006. PTEN regulates fibroblast elimination during collagen matrix contraction. J. Biol. Chem. 281:33291-301 (Pubitemid 46036712)
108. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, et al. 2009. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461:1084-91
109. Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, et al. 2006. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol. 168:292-309 (Pubitemid 43062581)
110. Tang W, Hemler ME. 2004. Caveolin-1 regulates matrix metalloproteinase 1 induction and CD147/EMMPRIN cell surface clustering. J. Biol. Chem. 279:11112-18 (Pubitemid 38401604)
111. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, et al. 2008. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol. Ther. 7:1212-25
112. Sotgia F, DelGaldo F, CasimiroMC, Bonuccelli G, Mercier I, et al. 2009. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am. J. Pathol. 174:746-61
113. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, et al. 2010. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 9:2423-33
114. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, et al. 2010. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: a new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 9:3256-76
115. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, et al. 2009. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8:3984-4001
116. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, et al. 2010. The autophagic tumor stroma model of cancer: role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 9:3485-505
117. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, et al. 2010. The autophagic tumor stroma model of cancer or "battery-operated tumor growth": a simple solution to the autophagy paradox. Cell Cycle 9:4297-306
118. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, et al. 2011. Stromalepithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int. J. Biochem. Cell Biol. 43:1045-51
119. Dang CV. 2009. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of theWarburg effect. Sci. Signal. 2:pe75
120. Dang CV. 2010. Rethinking theWarburg effect withMyc micromanaging glutamine metabolism. Cancer Res. 70:859-62
121. Jose C, Bellance N, Rossignol R. 2011. Choosing between glycolysis and oxidative phosphorylation: a tumor's dilemma? Biochim. Biophys. Acta 1807:552-61
122. Lopez-Lazaro M. 2007. Excessive superoxide anion generation plays a key role in carcinogenesis. Int. J. Cancer 120:1378-80
123. Rhee SG. 2006. Cell signaling. H2O2, a necessary evil for cell signaling. Science 312:1882-83 (Pubitemid 43993698)
124. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33
125. Gstraunthaler G, Seppi T, Pfaller W. 1999. Impact of culture conditions, culture media volumes, and glucose content on metabolic properties of renal epithelial cell cultures. Are renal cells in tissue culture hypoxic? Cell Physiol. Biochem. 9:150-72 (Pubitemid 29439100)
126. Zu XL, Guppy M. 2004. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 313:459-65 (Pubitemid 38021849)
127. Fan TW, Kucia M, Jankowski K, Higashi RM, Ratajczak J, et al. 2008. Rhabdomyosarcoma cells show an energy producing anabolic metabolic phenotype compared with primary myocytes. Mol. Cancer 7:79
128. de Groof AJ, te Lindert MM, vanDommelen MM, Wu M, Willemse M, et al. 2009. IncreasedOXPHOS activity precedes rise in glycolytic rate in H-RasV12/E1A transformed fibroblasts that develop aWarburg phenotype. Mol. Cancer 8:54
129. Griguer CE, Oliva CR, Gillespie GY. 2005. Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines. J. Neurooncol. 74:123-33 (Pubitemid 41478907)
130. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. 2004. Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res. 64:985-93 (Pubitemid 38176901)
131. Chen EI, Hewel J, Krueger JS, Tiraby C, Weber MR, et al. 2007. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67:1472-86 (Pubitemid 46383371)
132. Osthus RC, Shim H, Kim S, Li Q, Reddy R, et al. 2000. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275:21797-800 (Pubitemid 30621745)
133. Li F, Wang Y, Zeller KI, Potter JJ, Wonsey DR, et al. 2005. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol. 25:6225-34 (Pubitemid 40946570)
134. Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y. 2005. Ras inhibition in glioblastoma downregulates hypoxia-inducible factor 1α, causing glycolysis shutdown and cell death. Cancer Res. 65:999-1006 (Pubitemid 40216462)
135. Dejean L, Beauvoit B, Bunoust O, Guerin B, Rigoulet M. 2002. Activation of Ras cascade increases the mitochondrial enzyme content of respiratory competent yeast. Biochem. Biophys. Res. Commun. 293:1383-88 (Pubitemid 34681030)
136. Morrish F, Neretti N, Sedivy JM, Hockenbery DM. 2008. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7:1054-66
137. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. USA 104:19345-50
138. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, et al. 2009. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458:762-65
139. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, et al. 2010. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18:207-19
140. Sheen-Chen SM, Huang CC, Tang RP, Chou FF, EngHL. 2008. Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol. Biomarkers Prev. 17:2286-90
141. Min H, Wei-Hong Z. 2009. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J. Obstet. Gynaecol. Res. 35:918-25
142. Lee J, Kang WK, Park JO, Park SH, Park YS, et al. 2009. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. Acta Pathol. Microbiol. Immunol. 117:598-606
143. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. 2009. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324:1713-16
144. Fogal V, Richardson AD, Karmali PP, Scheffler IE, Smith JW, Ruoslahti E. 2010. Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol. Cell. Biol. 30:1303-18
145. Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, et al. 2011. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. Cancer Sci. 102:639-47
146. Weinberg F, Hamanaka R, WheatonWW, Weinberg S, Joseph J, et al. 2010. Mitochondrial metabolism and ROS generation are essential forKras-mediated tumorigenicity. Proc.Natl. Acad. Sci. USA 107:8788-93
147. Toki N, Kagami S, Kurita T, Kawagoe T, Matsuura Y, et al. 2010. Expression of mitochondrial transcription factor A in endometrial carcinomas: clinicopathologic correlations and prognostic significance. Virchows Arch. 456:387-93
148. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, et al. 2005. Breast carcinomas fulfill theWarburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 26:2095-104 (Pubitemid 41672197)
149. Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, et al. 2003. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 3:1801-10 (Pubitemid 37129826)
150. Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, et al. 2010. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann. Oncol. 21:187-89
151. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. 2009. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-88
152. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27:3297-302
153. Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Part 3):607-14 (Pubitemid 30410251)
154. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, et al. 2007. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67:6745-52 (Pubitemid 47105521)
155. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, et al. 2010. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70:2465-75
156. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. 1998. Lactic acidosis in patients with diabetes treated with metformin. N. Engl. J. Med. 338:265-6 (Pubitemid 28047587)
157. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
158. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 19:17-30
159. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. 2009. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261-65
160. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, et al. 2011. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc. Natl. Acad. Sci. USA 108:3270-75
161. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, et al. 2002. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30:406-10
162. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, et al. 2000. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848-51 (Pubitemid 30084326)
163. Mayr JA, Meierhofer D, Zimmermann F, Feichtinger R, Kogler C, et al. 2008. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin. Cancer Res. 14:2270-75 (Pubitemid 351551057)
164. Zimmermann FA, Mayr JA, Feichtinger R, Neureiter D, Lechner R, et al. 2011. Respiratory chain complex I is a mitochondrial tumor suppressor of oncocytic tumors. Front Biosci. 3:315-25
165. Dimauro S. 2011. A history of mitochondrial diseases. J. Inherit. Metab. Dis. 34:261-76
166. DiMauro S, Schon EA. 2003. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348:2656-68 (Pubitemid 36741594)
167. DiMauro S, Gurgel-Giannetti J. 2005. The expanding phenotype of mitochondrial myopathy. Curr. Opin. Neurol. 18:538-42 (Pubitemid 41476139)
168. Quinzii CM, Hirano M, DiMauro S. 2007. CoQ10 deficiency diseases in adults. Mitochondrion 7(Suppl.):122-26
169. Yokota M, Shitara H, Hashizume O, Ishikawa K, Nakada K, et al. Generation of trans-mitochondrial mito-mice by the introduction of a pathogenicG13997A mtDNA from highlymetastatic lung carcinoma cells. FEBS Lett. 584:3943-48
170. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, et al. 2010. The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 9:1960-71
171. Ramanathan A, Wang C, Schreiber SL. 2005. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc. Natl. Acad. Sci. USA 102:5992-97 (Pubitemid 40594243)
172. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, et al. 2010. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 9:2412-22
173. Wang J, Ying G, Jung Y, Lu J, Zhu J, et al. 2010. Characterization of phosphoglycerate kinase 1 expression of stromal cells derived from tumormicroenvironment in prostate cancer progression. Cancer Res. 70:471-80
174. Tang SJ, Ho MY, Cho HC, Lin YC, Sun GH, et al. 2008. Phosphoglycerate kinase 1-overexpressing lung cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. Int. J. Cancer 123:2840-48
175. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, et al. 2010. HIF1-α functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 9:3534-51
176. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, et al. 2010. Ketones and lactate "fuel" tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 9:3506-14
177. Koukourakis MI, Kontomanolis E, Giatromanolaki A, Sivridis E, Liberis V. 2009. Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. Gynecol. Obstet. Investig. 67:162-68
178. Kayser G, Kassem A, SienelW, Schulte-Uentrop L, Mattern D, et al. 2010. Lactate-dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1. Diagn. Pathol. 5:22
179. Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, et al. 2003. Lactate dehydrogenase 5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br. J. Cancer 89:877-85 (Pubitemid 37175811)
180. Ross CD, Gomaa MA, Gillies E, Juengel R, Medina JE. 2000. Tumor grade, microvessel density, and activities of malate dehydrogenase, lactate dehydrogenase, and hexokinase in squamous cell carcinoma. Otolaryngol. Head Neck Surg. 122:195-200 (Pubitemid 30086138)
181. Koukourakis MI, Giatromanolaki A, Winter S, Leek R, Sivridis E, Harris AL. 2009. Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy. Oncology 77:285-92
182. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. 2006. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway-a report of the Tumour Angiogenesis Research Group. J. Clin. Oncol. 24:4301-8 (Pubitemid 46630788)
183. Giatromanolaki A, Sivridis E, Gatter KC, Turley H, Harris AL, Koukourakis MI. 2006. Lactate dehydrogenase 5 (LDH-5) expression in endometrial cancer relates to the activated VEGF/VEGFR2(KDR) pathway and prognosis. Gynecol. Oncol. 103:912-18 (Pubitemid 44821314)
184. Lyshchik A, Higashi T, Hara T, Nakamoto Y, Fujimoto K, et al. 2007. Expression of glucose transporter 1, hexokinase II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Investig. 25:154-62 (Pubitemid 47164858)
185. Herst PM, Howman RA, Neeson PJ, Berridge MV, Ritchie DS. 2011. The level of glycolyticmetabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome. J. Leukoc. Biol. 89:51-55
186. Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, et al. 2008. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Investig. 118:3930-42
187. Bouzier AK, Voisin P, Goodwin R, Canioni P, Merle M. 1998. Glucose and lactate metabolism in C6 glioma cells: evidence for the preferential utilization of lactate for cell oxidative metabolism. Dev. Neurosci. 20:331-38 (Pubitemid 28495527)
188. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. 2006. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumorassociated stroma. Cancer Res. 66:632-37 (Pubitemid 43165922)
189. Magistretti PJ, Pellerin L. 1996. The contribution of astrocytes to the 18F-2-deoxyglucose signal in PET activation studies. Mol. Psychiatry 1:445-52 (Pubitemid 126439784)
190. Magistretti PJ. 2006. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol. 209:2304-11 (Pubitemid 44065524)
191. Magistretti PJ. 2009. Role of glutamate in neuron-glia metabolic coupling.Am. J. Clin.Nutr. 90:875-80S
192. Tsacopoulos M, Magistretti PJ. 1996. Metabolic coupling between glia and neurons. J. Neurosci. 16:877-85 (Pubitemid 26140843)
193. Laughton JD, Bittar P, Charnay Y, Pellerin L, Kovari E, et al. 2007. Metabolic compartmentalization in the human cortex and hippocampus: evidence for a cell- and region-specific localization of lactate dehydrogenase 5 and pyruvate dehydrogenase. BMC Neurosci. 8:35
194. Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. 2004. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 305:99-103 (Pubitemid 38869381)
195. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, et al. 2010. Autophagy in cancer associated fibroblasts promotes tumor cell survival: role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 9:3515-33
196. Frerart F, Lobysheva I, Gallez B, Dessy C, Feron O. 2009. Vascular caveolin deficiency supports the angiogenic effects of nitrite, a major end product of nitric oxide metabolism in tumors. Mol. Cancer Res. 7:1056-63
197. Kobayashi Y. 2010. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J. Leukoc. Biol. 88:1157-62
198. Riobo NA, Clementi E, Melani M, Boveris A, Cadenas E, et al. 2001. Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation. Biochem. J. 359:139-45 (Pubitemid 32939215)
199. Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, et al. 2010. Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": a transcriptional informatics analysis with validation. Cell Cycle 9:2201-19
200. Chen X, WhitingC, Borza C, Hu W, Mont S, et al. 2010. Integrinβ1β1 regulates epidermal growth factor receptor activation by controlling peroxisome proliferator-activated receptorα-dependent caveolin-1 expression. Mol. Cell. Biol. 30:3048-58
201. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, et al. 2004. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 53:1261-70 (Pubitemid 38569012)
202. Cohen AW, Schubert W, Brasaemle DL, Scherer PE, Lisanti MP. 2005. Caveolin-1 expression is essential for proper nonshivering thermogenesis in brown adipose tissue. Diabetes 54:679-86 (Pubitemid 40326265)
203. Schubert W, Sotgia F, Cohen AW, Capozza F, Bonuccelli G, et al. 2007. Caveolin-1-/- and caveolin- 2-/-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. Am. J. Pathol. 170:316-33 (Pubitemid 47339210)
204. Fernandez MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, et al. 2006. Caveolin-1 is essential for liver regeneration. Science 313:1628-32 (Pubitemid 44414035)
205. Trimmer C, Sotgia F, Whitaker-Menezes D, Balliet RM, Eaton G, et al. 2011. Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: a new genetically tractable model for human cancer associated fibroblasts. Cancer Biol. Ther. 11:383-94
206. Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, et al. 2010. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2:211-30
207. Tobar N, Guerrero J, Smith PC, Martinez J. 2010. NOX4-dependent ROS production by stromal mammary cells modulates epithelial MCF-7 cell migration. Br. J. Cancer 103:1040-47
208. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, et al. 2011. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol. Endocrinol. 25:503-15
209. Sivridis E, Giatromanolaki A, Koukourakis MI. 2005. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J. Clin. Pathol. 58:1033-38 (Pubitemid 41416051)
210. Kuijper A, van der Groep P, van der Wall E, van Diest PJ. 2005. Expression of hypoxia-inducible factor 1αand its downstream targets in fibroepithelial tumors of the breast. Breast Cancer Res. 7:R808-18
211. Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, et al. 2009. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 115:2732-43
212. Cleven AH, van Engeland M, Wouters BG, de Bruine AP. 2007. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol. 29:229-40 (Pubitemid 46855703)
213. Simon F, Bockhorn M, Praha C, Baba HA, Broelsch CE, et al. 2010. Deregulation of HIF1-α and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue- influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch. Surg. 395:395-405
214. Hyoudou K, Nishikawa M, Umeyama Y, Kobayashi Y, Yamashita F, Hashida M. 2004. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysiswith firefly luciferase-expressing melanoma cells. Clin. Cancer Res. 10:7685-91 (Pubitemid 39557533)
215. Nishikawa M, Hyoudou K, Kobayashi Y, Umeyama Y, Takakura Y, Hashida M. 2005. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J. Control. Release 109:101-7 (Pubitemid 41737256)
216. Hyoudou K, Nishikawa M, Kobayashi Y, Umeyama Y, Yamashita F, Hashida M. 2006. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic. Biol.Med. 41:1449-58 (Pubitemid 44466729)
217. Nishikawa M, Hashida M, Takakura Y. 2009. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv. Drug Deliv. Rev. 61:319-26
218. Hyoudou K, Nishikawa M, Ikemura M, Kobayashi Y, Mendelsohn A, et al. 2009. Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. J. Control. Release 137:110-15
219. Nishikawa M, Tamada A, Hyoudou K, Umeyama Y, Takahashi Y, et al. 2004. Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin. Exp. Metastasis 21:213-21 (Pubitemid 39158498)
220. Hyoudou K, Nishikawa M, Kobayashi Y, Ikemura M, Yamashita F, Hashida M. 2008. SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin. Exp. Metastasis 25:531-36
221. van Rossen ME, Sluiter W, Bonthuis F, Jeekel H, Marquet RL, van Eijck CH. 2000. Scavenging of reactive oxygen species leads to diminished peritoneal tumor recurrence. Cancer Res. 60:5625-29
222. Zhao Y, Xue Y, Oberley TD, Kiningham KK, Lin SM, et al. 2001. Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein 1 signaling in a multistage skin carcinogenesis model. Cancer Res. 61:6082-88 (Pubitemid 32762543)
223. Vozenin-Brotons MC, Sivan V, Gault N, Renard C, Geffrotin C, et al. 2001. Antifibrotic action of Cu/Zn SOD is mediated by TGF-β1 repression and phenotypic reversion of myofibroblasts. Free Radic. Biol. Med. 30:30-42 (Pubitemid 32008086)
224. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, et al. 2009. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 29:2570-81
225. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, et al. 2008. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 283:10892-903
226. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, et al. 2009. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69:4918-25
227. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, et al. 2006. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66:10795-804 (Pubitemid 44876975)
228. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. 2009. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-14
229. Gherghiceanu M, Hinescu ME, Popescu LM. 2009. Myocardial interstitial Cajal-like cells (ICLC) in caveolin-1 KO mice. J. Cell Mol. Med. 13:202-6
230. Le Lay S, Briand N, Blouin CM, Chateau D, Prado C, et al. 2010. The lipoatrophic caveolin-1 deficient mouse model reveals autophagy in mature adipocytes. Autophagy 6:754-63
231. Bensaad K, Cheung EC, Vousden KH. 2009. Modulation of intracellular ROS levels byTIGAR controls autophagy. EMBO J. 28:3015-26
232. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. 2006. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107-20 (Pubitemid 44040989)
233. Zhao Y, Yang J, Liao W, Liu X, Zhang H, et al. 2010. Cytosolic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat. Cell Biol. 12:665-75
234. Eisenberg-Lerner A, Kimchi A. 2009. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 14:376-91
235. Futreal PA, Soderkvist P, Marks JR, Iglehart JD, CochranC, et al. 1992. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res. 52:2624-27
236. SaitoH, Inazawa J, Saito S, Kasumi F, Koi S, et al. 1993. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. Cancer Res. 53:3382-85 (Pubitemid 23223313)
237. Nicotra G, Mercalli F, Peracchio C, Castino R, Follo C, et al. 2010. Autophagy-active beclin-1 correlates with favourable clinical outcome in non-Hodgkin lymphomas. Mod. Pathol. 23:937-50
238. Li BX, Li CY, Peng RQ, Wu XJ, Wang HY, et al. 2009. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy 5:303-6
239. Ding ZB, Shi YH, Zhou J, Qiu SJ, Xu Y, et al. 2008. Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma. Cancer Res. 68:9167-75
240. Tan EY, Campo L, Han C, Turley H, Pezzella F, et al. 2007. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin. Cancer Res. 13:467-74 (Pubitemid 46225351)
241. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, et al. 2009. Autophagy suppresses tumorigenesis through elimination of p62. Cell 137:1062-75
242. Nomura H, Uzawa K, Yamano Y, Fushimi K, Ishigami T, et al. 2009. Overexpression and altered subcellular localization of autophagy-related 16-like 1 in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis. Hum. Pathol. 40:83-91
243. Kleer CG, Bloushtain-Qimron N, Chen YH, Carrasco D, Hu M, et al. 2008. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin. Cancer Res. 14:5357-67
244. Nadji M, Fresno M, Nassiri M, Conner G, Herrero A, Morales AR. 1996. Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node-negative breast cancer. Hum. Pathol. 27:890-95 (Pubitemid 26304566)
245. Patel BB, Li XM, Dixon MP, Blagoi EL, Nicolas E, et al. 2011. APC+/- alters colonic fibroblast proteome in FAP. Oncotarget 2:197-208
246. Fiucci G, Ravid D, Reich R, Liscovitch M. 2002. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21:2365-75 (Pubitemid 34413560)
247. Lu Z, Ghosh S, Wang Z, Hunter T. 2003. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of α-catenin, and enhanced tumor cell invasion. Cancer Cell 4:499-515 (Pubitemid 38050046)
248. Sloan EK, Stanley KL, Anderson RL. 2004. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23:7893-97 (Pubitemid 39457039)
249. Engelman JA, Zhang XL, Lisanti MP. 1998. Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett. 436:403-10 (Pubitemid 28482971)
250. Hayashi K, Matsuda S, Machida K, Yamamoto T, Fukuda Y, et al. 2001. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res. 61:2361-64 (Pubitemid 32685805)
251. Han SE, Park KH, Lee G, Huh YJ, Min BM. 2004. Mutation and aberrant expression of caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int. J. Oncol. 24:435-40
252. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, et al. 2006. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor α-positive status. Am. J. Pathol. 168:1998-2013 (Pubitemid 43825319)
253. Syeed N, Husain SA, Abdullah S, Sameer AS, Chowdri NA, et al. 2010. Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population. Asian Pac. J. Cancer Prev. 11:1099-105
254. Hurlstone AF, Reid G, Reeves JR, Fraser J, Strathdee G, et al. 1999. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene 18:1881-90 (Pubitemid 29145855)
255. Koike S, Kodera Y, Nakao A, Iwata H, Yatabe Y. 2010. Absence of the caveolin-1 P132L mutation in cancers of the breast and other organs. J. Mol. Diagn. 12:712-17
256. Bonuccelli G, Casimiro MC, Sotgia F, Wang C, Liu M, et al. 2009. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am. J. Pathol. 174:1650-62
257. Yamaguchi H, Takeo Y, Yoshida S, Kouchi Z, Nakamura Y, Fukami K. 2009. Lipid rafts and caveolin-1 are required for invadopodia formation and extracellular matrix degradation by human breast cancer cells. Cancer Res. 69:8594-602
258. SalatinoM, Beguelin W, Peters MG, Carnevale R, Proietti CJ, et al. 2006. Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene 25:7723-39 (Pubitemid 44967967)
259. Horiguchi A, Asano T, Asakuma J, Sumitomo M, Hayakawa M. 2004. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J. Urol. 172:718-22 (Pubitemid 38900248)
260. Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, et al. 2007. Immunohistochemical analysis with multiple antibodies in search of prognosticmarkers for clear cell renal cell carcinoma. Urology 69:843-48 (Pubitemid 46670242)
261. Campbell L, Gumbleton M, Griffiths DF. 2003. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br. J. Cancer 89:1909-13 (Pubitemid 37533269)
262. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF. 2008. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br. J. Cancer 98:931-40 (Pubitemid 351341603)
263. Yang G, Truong LD, Wheeler TM, Thompson TC. 1999. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59:5719-23
264. Satoh T, Yang G, Egawa S, Addai J, Frolov A, et al. 2003. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer 97:1225-33 (Pubitemid 36237308)
265. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. 2008. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer 59:105-10
266. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, et al. 2002. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94:929-33 (Pubitemid 34150846)
267. Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, et al. 2007. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol. Rep. 18:601-9
268. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, et al. 2002. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer 87:1140-44 (Pubitemid 35418110)
269. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, et al. 2007. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin. Cancer Res. 13:90-101 (Pubitemid 46121857)
270. Shi L, Chen XM, Wang L, Zhang L, Chen Z. 2007. Expression of caveolin-1 in mucoepidermoid carcinoma of the salivary glands: correlation with vascular endothelial growth factor, microvessel density, and clinical outcome. Cancer 109:1523-31 (Pubitemid 46595687)
271. Murakami S, Miyamoto M, Hida Y, Cho Y, Fukunaga A, et al. 2003. Caveolin-1 overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma. Br. J. Cancer 88:1234-38 (Pubitemid 36606339)
272. Yang SF, Yang JY, Huang CH, Wang SN, Lu CP, et al. 2010. Increased caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. Pathology 42:438-45
273. Bender FC, Reymond MA, Bron C, Quest AF. 2000. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60:5870-78
274. Lavie Y, Fiucci G, Liscovitch M. 1998. Up-regulation of caveolae and caveolar constituents in multidrugresistant cancer cells. J. Biol. Chem. 273:32380-83 (Pubitemid 28557607)
275. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, et al. 2007. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum. Pathol. 38:830-41 (Pubitemid 46726507)
276. Williams TM, HassanGS, Li J, Cohen AW, Medina F, et al. 2005. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 280:25134-45 (Pubitemid 40934606)
277. Lee H, Woodman SE, Engelman JA, Volonte D, Galbiati F, et al. 2001. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). J. Biol. Chem. 276:35150-58
278. Joshi B, Strugnell SS, Goetz JG, Kojic LD, Cox ME, et al. 2008. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res. 68:8210-20
279. Schlegel A, Arvan P, Lisanti MP. 2001. Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum. J. Biol. Chem. 276:4398-408
280. Tahir SA, Yang G, Ebara S, Timme TL, Satoh T, et al. 2001. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61:3882-85 (Pubitemid 32720945)
281. Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, et al. 2009. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumor grade and other prognostic factors. BMC Res. Notes 2:140
282. He Y, Franco OE, Jiang M, Williams K, Love HD, et al. 2007. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res. 67:8188-97 (Pubitemid 47395155)
283. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. 2003. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Investig. Ophthalmol. Vis. Sci. 44:1305-11 (Pubitemid 36297854)
284. Bergersen LH. 2007. Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience 145:11-19 (Pubitemid 46237686)
285. Brooks GA. 1991. Current concepts in lactate exchange. Med. Sci. Sports
286. Brooks GA. 2002. Lactate shuttles in nature. Biochem. Soc. Trans. 30:258-64
287. Brooks GA. 2007. Lactate: link between glycolytic and oxidative metabolism. Sports Med. 37:341-43 (Pubitemid 46698534)
288. Gladden LB. 2008. A lactatic perspective on metabolism. Med. Sci. Sports Exerc. 40:477-85
289. Hashimoto T, Masuda S, Taguchi S, Brooks GA. 2005. Immunohistochemical analysis ofMCT1, MCT2 and MCT4 expression in rat plantaris muscle. J. Physiol. 567:121-29 (Pubitemid 41167310)
290. Andrade BB, Reis-Filho A, Souza-Neto SM, Raffaele-Netto I, Camargo LM, et al. 2010. Plasma superoxide dismutase-1 as a surrogate marker of vivax malaria severity. PLoS Negl. Trop. Dis. 4:e650
291. Dey S, Guha M, Alam A, Goyal M, Bindu S, et al. 2009. Malarial infection develops mitochondrial pathology and mitochondrial oxidative stress to promote hepatocyte apoptosis. Free Radic. Biol. Med. 46:271-81
292. Elsheikha HM, El-Motayam MH, Abouel-Nour MF, Morsy AT. 2009. Oxidative stress and immunesuppression in Toxoplasma gondii positive blood donors: implications for safe blood transfusion. J. Egypt. Soc. Parasitol. 39:421-28
293. Karaman U, Celik T, Kiran TR, Colak C, Daldal NU. 2008. Malondialdehyde, glutathione, and nitric oxide levels in Toxoplasma gondii seropositive patients. Korean J. Parasitol. 46:293-95
294. Wen JJ, Gupta S, Guan Z, Dhiman M, Condon D, et al. 2010. Phenyl-α-tert-butyl-nitrone and benzonidazole treatment controlled the mitochondrial oxidative stress and evolution of cardiomyopathy in chronic chagasic rats. J. Am. Coll Cardiol. 55:2499-508
295. Romano PS, ArboitMA, Vazquez CL, ColomboMI. 2009. The autophagic pathway is a key component in the lysosomal dependent entry of Trypanosoma cruzi into the host cell. Autophagy 5:6-18
296. Wang Y, Karnataki A, Parsons M, Weiss LM, Orlofsky A. 2010. 3-Methyladenine blocks Toxoplasma gondii division prior to centrosome replication. Mol. Biochem. Parasitol. 173:142-53
297. Totino PR, Daniel-Ribeiro CT, Corte-Real S, de Fatima Ferreira-da-Cruz M. 2008. Plasmodium falciparum: Erythrocytic stages die by autophagic-like cell death under drug pressure. Exp. Parasitol. 118:478-86
298. Mercier I, Jasmin JF, Pavlides S, Minetti C, Flomenberg N, et al. 2009. Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders. Lab. Investig. 89:614-23
299. Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, et al. 2011. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 10:1794-809
300. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, et al. 2011. Ketones and lactate increase cancer cell "stemness, " driving recurrence, metastasis, and poor clinical outcome in breast cancer: achieving personalized medicine via metabolo-genomics. Cell Cycle 10:1271-86